Gentofte Hospital (Copenhagen University Hospital Gentofte) is located in Gentofte within Copenhagen in Denmark. Administratively, it is part of the hospital service of Region Hovedstaden. The hospital primarily serves the municipalities of Gentofte, Lyngby-Taarbæk, and Rudersdal, with a population of about 175,000.
Critically ill patients with acute leukemia often require an intensive care unit (ICU) admission. As major therapeutic advances have been made during the last decades, the aim of this study was to assess temporal trends in ICU mortality, and identify prognostic factors to inform clinician decision-making. We conducted an individual participant data meta-analysis of studies including adults with acute leukemia admitted to the ICU. Patients with a history of allogeneic hematopoietic stem cell transplantation were excluded. Mixed-effects logistic regression models, accounting for center of ICU admission as a random variable, evaluated factors associated with ICU mortality, with particular focus on year of ICU admission, age (> 65 years) and invasive mechanical ventilation. A total of 2003 patients from 55 ICUs across 19 countries were included (median age 58 years [IQR 44–67]; 72
The present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed-type hypersensitivity skin and mucosal conditions. Sections with brief descriptions and discussions of different pertinent topics are followed by a highlighted short practical recommendation. Topics comprise, after an introduction with important definitions, materials, technique, modifications of epicutaneous testing, individual factors influencing the patch test outcome or necessitating special considerations, children, patients with occupational contact dermatitis and drug eruptions as special groups, patch testing of materials brought in by the patient, adverse effects of patch testing, and the final evaluation and patient counselling based on this judgement. Finally, short reference is made to aspects of (continuing) medical education and to electronic collection of data for epidemiological surveillance.
Oral Janus kinase inhibitors (JAKi) have proven effective in the treatment of atopic dermatitis (AD) in multiple clinical trials, providing rapid response, deep efficacy when given at the highest formulated dose, and in the case of abrocitinib and upadacitinib, superiority to biologics treatments in the first 4–16 weeks. However, it is unclear how this translates to real-world efficacy and safety. To assess the real-world effectiveness and safety of abrocitinib, baricitinib and upadacitinib in the treatment of AD. PubMed and EMBASE were systematically searched from inception until 3 January 2025 for observational studies investigating effectiveness and safety of abrocitinib, baricitinib and upadacitinib for the treatment of AD. The primary outcomes were the proportion of patients achieving a ≥ 75
MOTIVATION:Temporal multivariate data is ubiquitous in many domains, for instance, being collected over time at planned visits (every few months/years) in longitudinal cohorts, or every few minutes/hours in challenge tests. The analysis of such data often focuses on revealing the underlying temporal patterns common across subjects. However, there are subject-specific differences in temporal patterns, which hold the promise to enhance our understanding of underlying mechanisms and facilitate personalized approaches. Nevertheless, extracting subject-specific temporal patterns from longitudinal multivariate data reliably is an open challenge. RESULTS:We introduce coupled matrix factorizations (CMF) as effective tools to capture subject-specific temporal patterns focusing on two novel applications: analysis of longitudinal metabolomics data and sensitization data. Our analysis shows that CMF models reliably capture subject-specific (shape) differences in temporal patterns with the promise to reveal further insights compared to the state of the art. In metabolomics, CMF models reveal differences in metabolic responses of individuals (in a postprandial meal challenge) according to anthropometric and insulin sensitivity measures. In sensitization data analysis, CMF-based methods capture differences in temporal trajectories of children according to delivery/birth mode and atopic disease diagnosis. We demonstrate the reliability of extracted patterns using reproducibility and replicability. AVAILABILITY:The code is available on github.com/cchatzis/Revealing-Subject-specific-Temporal-Patterns-from-Longitudinal-Data and doi.org/10.5281/zenodo.22084338. Clinical data is not publicly available due to privacy reasons. Data can be made available under a joint research collaboration by contacting COPSAC (administration@dbac.dk).
Background:Systemic corticosteroid use in severe asthma is associated with morbidity and mortality. Little is known about the long-term corticosteroid burden prior to biologic therapy. This study aims to estimate the cumulative corticosteroid burden in patients initiating biologic therapy and impact of pre-biologic disease trajectories on corticosteroid burden. Methods:Patients in the Danish Severe Asthma Register initiating biologic therapy between 2016 and 2022 had their redemptions of inhaled, nasal and systemic corticosteroids from 1995 until first administration of biologic therapy retrieved. Prednisolone-equivalent doses were calculated for all redeemed corticosteroids, presented as either cumulative or daily exposure. Results:A total of 542 patients (median follow-up 16 years) were included. Prior to biologic initiation, the median (IQR) total corticosteroid burden during follow-up was 17.1 g (8.4-36.2) of which 7.2 g (3.3-16.3) were systemic corticosteroids. 56.3% of patients were exposed to more systemic than inhaled corticosteroids. Two-thirds of patients experienced a corticosteroid exposure ≥5 mg prednisolone equivalents daily in the year prior to biologic therapy. Additionally, 10% had inhaled corticosteroid exposure ≥5 mg daily prednisolone equivalents for over two decades. Cumulative exposure was highest in chronic severe asthma patients compared to those with gradual- or recent-onset severe asthma. 72% (12.4 g (3.9-34.2)) of total corticosteroid exposure occurred prior to the first registered specialist visit. Conclusion:Patients with severe asthma have substantial cumulative corticosteroid exposure prior to biologic therapy, with the majority occurring prior to specialist assessment. Exposure reduction is a key priority to minimise corticosteroid exposure-related comorbidities.
